Medco Decision To Avoid “At-Risk” Medicare Rx Plans Is “Premature,” CMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
PBMs should wait to see Part D implementing regs before deciding whether to offer a stand-alone drug plan, CMS’ Trysla says. PCMA and CMS Administrator McClellan discuss Medco’s position on the drug benefit.